The potential clinical implication of therapeutically targeting RAD50 in cancers has been demonstrated by dominant negative disruption of RAD50, conferring sensitization to platinum-based chemotherapy in squamous cell carcinoma [31]. The gene discussed is RAD50; the disease is cancer.